NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NGM Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014051
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NGM Biopharmaceuticals Inc (NGM Bio) is a clinical stage biopharmaceutical company which focuses on the development of drug discovery platform to generate biologic drug candidates to treat cardio-metabolic, immuno-oncology and liver diseases. Its product pipeline includes NGM282, NGM386, NGM395, NGM313, NGM217 and NGM120. The company’s drug candidates are being developed for the treatment of various therapeutic indications such as obesity, diabetes, oncology and other indications. NGM Bio developed a biologics platform that incorporates multiple technologies to generate and screen monoclonal antibodies. The company works in collaboration with Merck to discover, develop and commercialize new biologic drugs. NGM Bio is headquartered in South San Francisco, California, the US.

NGM Biopharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NGM Biopharma Raises USD106 Million in Series E Financing 11
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 12
NGM Biopharma Raises USD20.7 Million in Series D Financing 13
NGM Biopharma Raises US$50 Million In Series C Venture Financing 14
NGM BioPharma Raises US$16.9 Million In Fourth Tranche Of Series B Financing 15
Partnerships 16
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 16
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 17
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 18
Licensing Agreements 19
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 19
Equity Offering 20
NGM Biopharma Plans IPO 20
NGM Biopharmaceuticals Inc – Key Competitors 21
NGM Biopharmaceuticals Inc – Key Employees 22
NGM Biopharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NGM Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NGM Biopharma Raises USD106 Million in Series E Financing 11
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 12
NGM Biopharma Raises USD20.7 Million in Series D Financing 13
NGM Biopharma Raises US$50 Million In Series C Venture Financing 14
NGM BioPharma Raises US$16.9 Million In Fourth Tranche Of Series B Financing 15
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 16
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 17
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 18
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 19
NGM Biopharma Plans IPO 20
NGM Biopharmaceuticals Inc, Key Competitors 21
NGM Biopharmaceuticals Inc, Key Employees 22

★海外企業調査レポート[NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Edison SpA (EDNR):電力:M&Aディール及び事業提携情報
    Summary Edison SpA (Edison), a subsidiary of Electricite de France S.A., is an energy company that explores, produces, develops and sells natural gas and crude oil in the Mediterranean Basin. The company generates and sells electricity; and develops, stores, transports and sells gas in Italy. Edison …
  • Qualicaps Inc:企業の戦略的SWOT分析
    Qualicaps Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • SandRidge Energy, Inc. (SD)-石油・ガス分野:企業M&A・提携分析
    Summary SandRidge Energy, Inc. (SandRidge) is an upstream energy company. It develops, explores for, and produces oil and natural gas in the Mid-Continent and Rockies regions of the US. In Mid-Continent, the company operates assets in Oklahoma and Kansas. In Rockies, SandRidge operates assets within …
  • GE Lighting LLC:企業の戦略的SWOT分析
    GE Lighting LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • ZAP (ZAAP):企業の財務・戦略的SWOT分析
    ZAP (ZAAP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potent …
  • Kennametal Inc (KMT):企業の財務・戦略的SWOT分析
    Kennametal Inc (KMT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • ABC arbitrage SA (ABCA):企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Eco (Atlantic) Oil & Gas Ltd (EOG):企業の財務・戦略的SWOT分析
    Summary Eco (Atlantic) Oil & Gas Ltd (Eco) is an oil and gas exploration and development company. The company’s business activities include acquisition, identification, and development of upstream petroleum projects across Africa. The company's projects include cooper license-PEL 030, Sharon license …
  • FlightSafety International Inc:企業の戦略・SWOT・財務情報
    FlightSafety International Inc - Strategy, SWOT and Corporate Finance Report Summary FlightSafety International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Lloyd’s Register Group Ltd:企業の戦略的SWOT分析
    Lloyd's Register Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • InnoPharma Inc-製薬・医療分野:企業M&A・提携分析
    Summary InnoPharma Inc (InnoPharma), a subsidiary of Pfizer Inc is a healthcare products provider that develops generic and pharmaceutical products. The company develops formulations, which include solutions, suspensions, lyophilized, emulsions, liposomes, lipid complexes, polypeptides and carbohydr …
  • Arris International Plc
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Singapore Petroleum Co Ltd:企業の戦略的SWOT分析
    Singapore Petroleum Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Edwards Lifesciences Corp (EW)-医療機器分野:企業M&A・提携分析
    Summary Edwards Lifesciences Corp (Edwards) is a global medical technology company, which focuses on the development, manufacture and marketing of products and technologies used for the treatment of structural heart disease and critical conditions. It develops and commercializes heart valve products …
  • Xi’an Catering Co., Ltd.:戦略・SWOT・企業財務分析
    Xi'an Catering Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Xi'an Catering Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Resilux NV:企業の戦略・SWOT・財務情報
    Resilux NV - Strategy, SWOT and Corporate Finance Report Summary Resilux NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ARxIUM-医療機器分野:企業M&A・提携分析
    Summary ARxIUM, formerly Intelligent Hospital Systems Inc, a subsidiary of Van Humbeck Family, is a medical device company that designs and manufactures automated solutions for the hospital pharmacy. The company’s products include RxWorks pro, workflow, inventory management, IV compounding system, h …
  • Washington University in St Louis:製薬・医療:M&Aディール及び事業提携情報
    Summary Washington University in St Louis (WUSTL), a subsidiary of University of Washington is an educational university which provides education and research services. The university provides various courses of bachelor’s, master’s, and doctoral degrees in a wide range of traditional and interdisci …
  • Aviragen Therapeutics Inc (AVIR)-医療機器分野:企業M&A・提携分析
    Summary Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases. It has four product candidates in clinical development which address viral infections, namely, vapendavir, ora …
  • Fenner PLC (FENR):企業の財務・戦略的SWOT分析
    Summary Fenner PLC (Fenner), a subsidiary of Michelin SCA, is a provider of reinforced polymer technology. The company operates in the areas of advanced engineered products and engineered conveyor solutions. Its product portfolio includes heavyweight conveyor belt, high performance polymer component …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆